Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing technologies for patients with cancer and diabetes,
today announced the appointment of Catherine M. Vaczy as executive vice
president and chief strategy officer and Michael T. Redman as executive vice
president and chief operating officer. These appointments follow on the heels
of Genprex’s Fast Track Designation for its lead drug candidate, its newly
licensed gene therapy for diabetes, and over $26 million capital raise that
will support funding of its clinical programs. “We are delighted to welcome
Catherine and Michael to our executive leadership team. They join us at an
exciting time as we advance our lead drug candidate into key clinical programs
in non-small cell lung cancer and pursue partnership opportunities for our
oncology platform and newly licensed gene therapy technology for diabetes,”
Genprex CEO Rodney Varner said in the news release. “Catherine and Michael each
have significant biotechnology company experience that enhances our
capabilities and will be instrumental in advancing our programs. Their combined
expertise in business development, corporate strategy, manufacturing, clinical
trial strategy and operations and regulatory affairs will be of great value as
we build Genprex into a leading gene therapy company bringing new treatment
options to patients in need. We are fortunate to have raised over $26 million
just prior to the current turmoil in the markets, significantly strengthening
our balance sheet and well positioning us financially as we execute on our
strategic plan.”
To view the full press release, visit http://ibn.fm/Et8s2
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing treatments for cancer and other serious
diseases. Genprex’s technologies are designed to administer disease-fighting
genes to provide new treatment options for large patient populations with
cancer and other serious diseases who currently have limited treatment options.
Genprex works with world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches for patients with cancer and other serious
diseases. The company’s lead product candidate, Oncoprex(TM) immunogene therapy
for non-small cell lung cancer (“NSCLC”), uses the company’s unique,
proprietary platform which delivers cancer-fighting genes by encapsulating them
into nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. In January 2020, the FDA granted Fast Track
Designation for Oncoprex in combination with AstraZeneca’s Tagrisso(R) for the
treatment of NSCLC. For more information, please visit the company’s website
at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment